

**Supplementary Table S1.** ICD-10 and billing codes for identification of diagnoses and medications

Comorbidity	ICD-10 code
Cataract	H25 (Senile cataract): H25.0, H25.1, H25.2, H25.8, H25.9 H26 (Other cataract): H26.0, H26.1, H26.2, H26.3, H26.4, H26.8, H26.9
Hypertension	I10 (Primary hypertension): I10.1, I10.9 I15 (Secondary hypertension): I15.0, I15.1, I15.2, I15.8, I15.9
Diabetes	E10 (Type 1 diabetes mellitus): E10.0, E10.1, E10.2, E10.3, E10.4, E10.5, E10.6, E10.7, E10.8, E10.9 E11 (Type 2 diabetes mellitus): E11.0, E11.1, E11.2, E11.3, E11.4, E11.5, E11.6, E11.7, E11.8, E11.9 E12 (Malnutrition-related diabetes mellitus): E12.0, E12.1, E12.2, E12.3, E12.4, E12.5, E12.6, E12.7, E12.8, E12.9 E13 (Other specified diabetes mellitus): E13.0, E13.1, E13.2, E13.3, E13.4, E13.5, E13.6, E13.7, E13.8, E13.9 E14 (Unspecified diabetes mellitus): E14.0, E14.1, E14.2, E14.3, E14.4, E14.5, E14.6, E14.7, E14.8, E14.9
Chronic liver disease	K70 (Alcoholic liver disease): K70.0, K70.1, K70.2, K70.3, K70.4, K70.9 K72 (Hepatic failure, NEC): K72.0, K72.1, K72.9 K73 (Chronic hepatitis): K73.0, K73.1, K73.2, K73.8, K73.9 K74 (Fibrosis and cirrhosis of liver): K74.0, K74.1, K74.2, K74.3, K74.4, K74.5, K74.6 B18 (Chronic viral hepatitis): B18.0, B18.1, B18.2, B18.8, B18.9
Chronic kidney disease	N18 (Chronic kidney disease): N18.1, N18.2, N18.3, N18.4, N18.5, N18.9 N03 (Chronic nephritic syndrome): N03.0, N03.1, N03.2, N03.3, N03.4, N03.5, N03.6, N03.7, N03.8, N03.9 N05 (Unspecified nephritic syndrome): N05.0, N05.1, N05.2, N05.3, N05.4, N05.5, N05.6, N05.7, N05.8, N05.9
Cardiovascular disease	I20 (Angina pectoris): I20.0, I20.1, I20.8, I20.9 I21 (Acute myocardial infarction): I21.0, I21.1, I21.2, I21.3, I21.4, I21.9 I22 (Subsequent myocardial infarction): I22.0, I22.1, I22.8, I22.9 I24 (Other acute ischemic heart disease): I24.0, I24.1, I24.8, I24.9 I25 (Chronic ischemic heart disease): I25.0, I25.1, I25.2, I25.3, I25.4, I25.5, I25.6, I25.8, I25.9 I50 (Heart failure): I50.0, I50.1, I50.9
Dyslipidemia	E78 (Disorders of lipoprotein metabolism and other lipidemia): E78.0, E78.1, E78.2, E78.4, E78.5
Parkinson's disease	G20 (Parkinson's disease)
Chronic pulmonary disease	J41 (Simple and mucopurulent chronic bronchitis): J41.0, J41.1, J41.8 J43 (Emphysema): J43.0, J43.1, J43.2, J43.8, J43.9 J44 (Other chronic obstructive pulmonary disease): J44.0, J44.1, J44.8, J44.9 J45 (Asthma): J45.0, J45.1, J45.8, J45.9 J47 (Bronchiectasis)

Myopia	H52.1 (Myopia)
Vitreous floaters	H43.38 (Other vitreous opacities)
Thyroid disease	E00 (Congenital iodine-deficiency syndrome): E00.0, E00.1, E00.2, E00.9 E03 (Other hypothyroidism): E03.0, E03.1, E03.2, E03.3, E03.4, E03.5, E03.8, E03.9 E05 (Thyrotoxicosis [hyperthyroidism]): E05.0, E05.1, E05.2, E05.3, E05.4, E05.5, E05.8, E05.9
<b>Medications</b>	<b>Billing Code</b>
GnRH agonists or antagonist	Degarelix: 624401BIJ, 624402BIJ Goserelin acetate: 167202BIJ, 167201BIJ Leuprorelin acetate: 182602BIJ, 182604BIJ, 182605BIJ, 182606BIJ, 182608BIJ, 182610BIJ, 182611BIJ Triptorelin acetate: 244902BIJ, 467501BIJ, 467502BIJ
Anti-androgens	Bicalutamide: 117201ATB, 117202ATB Cyproterone acetate: 139401ATB Flutamide: 162101ATB

GnRH = gonadotropin-releasing hormone; ICD-10 = International Classification of Diseases, 10th revision; NEC = not else classified.

**Supplementary Table S2.** Relationship between ADT and newly developed neovascular AMD (1:1 matching ratio)

	<b>Cases (n = 1738)</b> n (%)	<b>Controls (n = 1738)</b> n (%)	<b>Crude OR</b> <b>(95% CI)</b>	<b>P value</b>	<b>Adjusted OR</b> <b>(95% CI)<sup>a</sup></b>	<b>P value</b>
<b>ADT administration</b>						
Never	1256 (72.27)	1214 (69.85)	Reference		Reference	
Ever	482 (27.73)	524 (30.15)	0.879 (0.753-1.025)	0.0997	0.885 (0.757-1.035)	0.1249
<b>Cumulative duration of ADT</b>						
None	1256 (72.27)	1214 (69.85)	Reference		Reference	
<1 year	193 (11.10)	257 (14.79)	0.708 (0.573-0.875)	0.0014	0.713 (0.576-0.883)	0.0019
1-2 years	123 (7.08)	110 (6.33)	1.086 (0.820-1.439)	0.5648	1.072 (0.806-1.427)	0.6311
≥2 years	166 (9.55)	157 (9.03)	1.033 (0.807-1.321)	0.7983	1.057 (0.823-1.357)	0.6635

ADT = androgen deprivation therapy; AMD = age-related macular degeneration; OR = odds ratio; CI = confidence interval.

<sup>a</sup>adjusted for cataracts, hypertension, diabetes mellitus, chronic liver disease, chronic kidney disease, cardiovascular disease, dyslipidemia, Parkinson's disease, chronic pulmonary disease, myopia, vitreous floaters, and thyroid disease.

**Supplementary Table S3.** Relationship between ADT and newly developed neovascular AMD (1:10 matching ratio)

	<b>Cases (n = 1639)</b> n (%)	<b>Controls (n = 16390)</b> n (%)	<b>Crude OR</b> <b>(95% CI)</b>	<b>P value</b>	<b>Adjusted OR</b> <b>(95% CI)<sup>a</sup></b>	<b>P value</b>
<b>ADT administration</b>						
Never	1182 (72.12)	11342 (69.20)	Reference		Reference	
Ever	457 (27.88)	5048 (30.80)	0.859 (0.763-0.966)	0.0109	0.873 (0.776-0.982)	0.0242
<b>Cumulative duration of ADT</b>						
None	1182 (72.12)	11342 (69.20)	Reference		Reference	
<1 year	188 (11.47)	2295 (14.00)	0.770 (0.652-0.910)	0.0021	0.785 (0.664-0.928)	0.0046
1-2 years	116 (7.08)	1224 (7.47)	0.904 (0.734-1.112)	0.3382	0.909 (0.738-1.119)	0.3698
≥2 years	153 (9.33)	1529 (9.33)	0.960 (0.798-1.156)	0.6676	0.981 (0.814-1.182)	0.838

ADT = androgen deprivation therapy; AMD = age-related macular degeneration; OR = odds ratio; CI = confidence interval.

<sup>a</sup>adjusted for cataracts, hypertension, diabetes mellitus, chronic liver disease, chronic kidney disease, cardiovascular disease, dyslipidemia, Parkinson's disease, chronic pulmonary disease, myopia, vitreous floaters, and thyroid disease.